Michael Fuchs

TL;DR: This open-label, randomised, parallel-group phase 3 trial investigated whether metabolic response determined by PET after two cycles of standard regimen eBEACOPP (PET-2) would allow adaption of treatment intensity, increasing it for PET-2-positive patients and reducing it forPET- 2-negative patients and showed non-inferiority in the 5-year progression-free survival estimates.

TL;DR: Non-inferiority of the experimental variants compared with ABVD in terms of freedom from treatment failure (FFTF) is shown by excluding a difference of 6% after 5 years corresponding to a hazard ratio (HR) of 1.72, via a 95% CI.

TL;DR: Although treatment results with rituximab appear inferior compared with radiotherapy and combined-modality approaches in early-stage patients, investigation of anti-CD20 antibody-based combinations in NLPHL is warranted.

TL;DR: Long-term follow-up data of the four randomized trials largely support the current risk-adapted therapeutic strategies in early-stage HL, Nevertheless, continued follow- up is necessary to assess the long-term safety of currently applied therapeutic strategies.

TL;DR: No effects of bleomycin on toxicity rates were detectable in older patients receiving 2 cycles of chemotherapy, however, a high risk of severe toxicity ofBleomycin in older HL patients receiving more than two cycles of ABVD is found.